Abstract:BACKGROUND: Butyrylcholineesterase (BChE) is a therapeutic drug and its producing as a recombinant protein is an essential issue in biotechnology. One of the highlights in this regard is choosing the best host cells and plasmids. OBJECTIVES: The aim of this study is to evaluate the production of butyrylcholinesterase in Vero, HEK-293, and CHO cell lines using a dual promoter vector. MATERIAL AND METHODS: The dual-promoter construction (pBudCE dual BChE) was transfected into cell lines categorized in three expe… Show more
“…After 24h of incubation, the medium was changed with 100 µl of CUR and CC-CUR nanocomposite in serum-free medium without antibiotics. RNA extraction was done according to a published protocol (23).…”
Breast cancer is one of the most common diseases worldwide. miR-221 and miR-222 are two microRNAs with pivotal roles in many cellular processes which regulate the Wnt/β-catenin pathway. Curcumin (CUR), a yellow polyphenolic compound, targets numerous pathways relevant to cancer therapy. The main aim of this study was to compare the ability of chitosan curcumin nanoparticle (CC-CUR) with the curcumin in modulating miR-221 and miR-222 expression through Wnt/β-catenin pathway in MCF-7, MDA-MB-231 and SK-BR-3 breast cancer cells. Chitosan-cyclodextrin-tripolyphosphate containing curcumin nanoparticles (CC-CUR) were prepared. Experimental groups including CC-CUR, CUR and negative control were designed. The expression of miR-221 and miR-222 and Wnt/β-catenin pathway genes was measured. The level of miR-221 and miR-222 and β-catenin genes decreased in MCF-7 and MDA-MB-231 cells and WIF1 gene increased in all cells in CC-CUR group. However, in SK-BR-3 cells miRs and WIF1 gene expressions were increased following CC-CUR administration and β-catenin decreased by administration of CUR. Significant decreasing of β-catenin and increasing of WIF1 gene in almost all three cell lines, indicates that this formulation exerts its effect mainly through the Wnt/β-catenin pathway. These preliminary findings may pave the way for the use of curcumin nanoparticles in the treatment of some known cancers.
“…After 24h of incubation, the medium was changed with 100 µl of CUR and CC-CUR nanocomposite in serum-free medium without antibiotics. RNA extraction was done according to a published protocol (23).…”
Breast cancer is one of the most common diseases worldwide. miR-221 and miR-222 are two microRNAs with pivotal roles in many cellular processes which regulate the Wnt/β-catenin pathway. Curcumin (CUR), a yellow polyphenolic compound, targets numerous pathways relevant to cancer therapy. The main aim of this study was to compare the ability of chitosan curcumin nanoparticle (CC-CUR) with the curcumin in modulating miR-221 and miR-222 expression through Wnt/β-catenin pathway in MCF-7, MDA-MB-231 and SK-BR-3 breast cancer cells. Chitosan-cyclodextrin-tripolyphosphate containing curcumin nanoparticles (CC-CUR) were prepared. Experimental groups including CC-CUR, CUR and negative control were designed. The expression of miR-221 and miR-222 and Wnt/β-catenin pathway genes was measured. The level of miR-221 and miR-222 and β-catenin genes decreased in MCF-7 and MDA-MB-231 cells and WIF1 gene increased in all cells in CC-CUR group. However, in SK-BR-3 cells miRs and WIF1 gene expressions were increased following CC-CUR administration and β-catenin decreased by administration of CUR. Significant decreasing of β-catenin and increasing of WIF1 gene in almost all three cell lines, indicates that this formulation exerts its effect mainly through the Wnt/β-catenin pathway. These preliminary findings may pave the way for the use of curcumin nanoparticles in the treatment of some known cancers.
“…After 24 h of incubation, the medium was changed with 100 μl of CUR and CC-CUR nanocomposite in serum-free medium without antibiotics. RNA extraction was done according to a published protocol [23].…”
Background
Breast cancer is one of the most common diseases worldwide that affects women of reproductive age. miR-221 and miR-222 are two highly homogeneous microRNAs that play pivotal roles in many cellular processes and regulate the Wnt/β-catenin signaling pathway. Curcumin (CUR), a yellow polyphenolic compound, targets numerous signaling pathways relevant to cancer therapy. The main aim of this study was to compare the ability of chitosan curcumin nanoparticle (CC-CUR) formulation with the curcumin in modulating miR-221 and miR-222 expression through Wnt/β-catenin signaling pathway in MCF-7, MDA-MB-231 and SK-BR-3 breast cancer cell lines.
Method
Chitosan-cyclodextrin-tripolyphosphate containing curcumin nanoparticles (CC-CUR) were prepared. Cytotoxicity of the CUR and CC-CUR was evaluated. Experimental groups including CC-CUR, CUR and negative control were designed. The expression of miR-221 and miR-222 and Wnt/β-catenin pathway genes was measured.
Results
The level of miR-221 and miR-222 and β-catenin genes decreased in MCF-7 and MDA-MB-231 cells and WIF1 gene increased in all cells in CC-CUR group. However, the results in SK-BR-3 cell line were unexpected; since miRs and WIF1 gene expressions were increased following CC-CUR administration and β-catenin decreased by administration of CUR.
Conclusion
Although the composite form of curcumin decreased the expression of miR-221 and miR-222 in MCF-7 and MDA cells, with significant decreasing of β-catenin and increasing of WIF1 gene in almost all three cell lines, we can conclude than this formulation exerts its effect mainly through the Wnt/β-catenin pathway. These preliminary findings may pave the way for the use of curcumin nanoparticles in the treatment of some known cancers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.